Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning

Abstract

Get full access to this article

View all access options for this article.

References

Cree

De Seze

Fox

. RESTORE Study: Effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis Magnetic Resonance Imaging disease activity. Neurology 2012; 78: P06.168

O’Connor

Goodman

Kappos

. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858–1865.

Vellinga

Castelijns

Barkhof

. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70: 1150–1151. Epub ahead of publication 13 September 2007.

Killestein

Vennegoor

Strijbis

. Natalizumab drug holiday in multiple sclerosis: Poorly tolerated. Ann Neurol 2010; 68: 392–395.

Miller

Khan

Sheremata

Blumhardt

Rice

, for the international natalizumab multiple sclerosis trial group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15–23.

Borriello

Prosperini

Marinelli

Fubelli

Pozzilli

. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler 2011; 17: 372–5.

West

Cree

. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 2010; 68: 395–9.

Miravalle

Jensen

Kinkel

. Immune reconstitution inflammatory symdrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68: 186–91.

Kerbrat

Le Page

Leray

. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 2011; 308: 98–102.

10.

Hellwig

Haghikia

Gold

Pregnancy and natalizumab: Results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011; 17: 958–963.